Actuate Therapeutics, Inc.

Actuate Therapeutics, Inc. company information, Employees & Contact Information

Explore related pages

Actuate Therapeutics, Inc. email format Actuate Therapeutics, Inc. management contacts

Related company profiles:

Actuate Therapeutics, Inc. (NASDAQ: ACTU) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment of high-impact, difficult-to-treat cancers. Actuate’s lead investigational drug product, elraglusib (a novel GSK-3β inhibitor), targets molecular pathways in cancer that are involved in promoting tumor growth and resistance to conventional cancer drugs such as chemotherapy including several DNA Damage Response (DDR) pathways. Elraglusib is designed to act as a mediator of anti-tumor immunity through the inhibition of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) and regulates multiple immune checkpoints and immune cell function. For additional information, please visit the Company’s website at http://www.actuatetherapeutics.com.

Company Details

Employees
14
Founded
-
Address
1751 River Run,
Phone
(847) 986-4190
Email
in****@****ics.com
Industry
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing
Medicinal and Botanical Manufacturing
Pharmaceutical Preparation Manufacturing
In-Vitro Diagnostic Substance Manufacturing
Biological Product (except Diagnostic) Manufacturing
Website
actuatetherapeutics.com
Keywords
Representative jobs.
HQ
Fort Worth, Texas
Competitors
Lykos Therapeutics, Crown Laboratories (a Revance company), ARS Pharmaceuticals, Inc., CymaBay Therapeutics, Ascendis Pharma, Ovid Therapeutics, Tevard Biosciences, Zealand Pharma, Syros Pharmaceuticals, Halda Therapeutics.
Looking for a particular Actuate Therapeutics, Inc. employee's phone or email?

Actuate Therapeutics, Inc. Questions

News

Actuate Therapeutics Provides FDA with Updated Clinical - GlobeNewswire

Actuate Therapeutics Provides FDA with Updated Clinical GlobeNewswire

Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy - Yahoo Finance

Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy Yahoo Finance

Actuate Therapeutics Announces Closing of $17.25 Million - GlobeNewswire

Actuate Therapeutics Announces Closing of $17.25 Million GlobeNewswire

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer - Yahoo Finance

Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer Yahoo Finance

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock - GlobeNewswire

Actuate Therapeutics Announces Pricing of $15.0 Million Public Offering of Common Stock GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewswire

Actuate Therapeutics Announces Proposed Public Offering of Common Stock GlobeNewswire

Elraglusib Plus Chemotherapy Extends OS vs Chemotherapy Alone in Frontline Metastatic PDAC - OncLive

Elraglusib Plus Chemotherapy Extends OS vs Chemotherapy Alone in Frontline Metastatic PDAC OncLive

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer - GlobeNewswire

Actuate Therapeutics To Collaborate with Incyte Corporation and the University of Pittsburgh on Clinical Trial of Elraglusib in Combination with Retifanlimab and mFOLFIRINOX in Patients with Advanced Pancreatic Cancer GlobeNewswire

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20% - Yahoo Finance

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) largest shareholders are private equity firms with 62% ownership, institutions own 20% Yahoo Finance

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial - GlobeNewswire

Actuate Therapeutics Highlights Significant and Sustained Survival Benefit in Key Metastatic Pancreatic Cancer Patient Populations in Phase 2 Elraglusib Trial GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 - GlobeNewswire

Actuate Therapeutics to Participate in Citizens Life Sciences Conference 2025 GlobeNewswire

Actuate Therapeutics shares highlights from KOL eventon elraglusib data - Yahoo Finance

Actuate Therapeutics shares highlights from KOL eventon elraglusib data Yahoo Finance

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes - GlobeNewswire

Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes GlobeNewswire

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer - GlobeNewswire

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer GlobeNewswire

Actuate Therapeutics Announces Closing of Initial Public Offering - GlobeNewswire

Actuate Therapeutics Announces Closing of Initial Public Offering GlobeNewswire

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor - Yahoo Finance

Actuate Announces Scientific Reports Publication on Elraglusib’s Novel Immunomodulatory Mechanism of Action as a GSK-3β Inhibitor Yahoo Finance

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? - Yahoo Finance

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Deliver On Growth Plans? Yahoo Finance

FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma - Targeted Oncology

FDA Grants Elraglusib Orphan Drug Designation in Soft Tissue Sarcoma Targeted Oncology

Elraglusib Gains FDA Rare Pediatric Disease Designation in Ewing Sarcoma - Targeted Oncology

Elraglusib Gains FDA Rare Pediatric Disease Designation in Ewing Sarcoma Targeted Oncology

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer - Stocktwits

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer Stocktwits

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth? - simplywall.st

Is Actuate Therapeutics (NASDAQ:ACTU) In A Good Position To Invest In Growth? simplywall.st

Actuate Therapeutics (NASDAQ:ACTU) Shares Slide Amid Update Nasdaq Composite - Kalkine Media

Actuate Therapeutics (NASDAQ:ACTU) Shares Slide Amid Update Nasdaq Composite Kalkine Media

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform - PR Newswire

Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform PR Newswire

Companies like Actuate Therapeutics, Inc.

Lykos Therapeutics logo - Similar company to Actuate Therapeutics, Inc.

Lykos Therapeutics

90
Crown Laboratories (a Revance company) logo - Similar company to Actuate Therapeutics, Inc.

Crown Laboratories (...

505
Ovid Therapeutics logo - Similar company to Actuate Therapeutics, Inc.

Ovid Therapeutics

39
CymaBay Therapeutics logo - Similar company to Actuate Therapeutics, Inc.

Cymabay Therapeutics

35
Halda Therapeutics logo - Similar company to Actuate Therapeutics, Inc.

Halda Therapeutics

46
Ascendis Pharma logo - Similar company to Actuate Therapeutics, Inc.

Ascendis Pharma

1.19K
ARS Pharmaceuticals, Inc. logo - Similar company to Actuate Therapeutics, Inc.

Ars Pharmaceuticals,...

163
Zealand Pharma logo - Similar company to Actuate Therapeutics, Inc.

Zealand Pharma

476
Tevard Biosciences logo - Similar company to Actuate Therapeutics, Inc.

Tevard Biosciences

35
Syros Pharmaceuticals logo - Similar company to Actuate Therapeutics, Inc.

Syros Pharmaceuticals

30

Top Actuate Therapeutics, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant